Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 11.99$. Average daily volumn in 3 months 955.64k. Market cap 11.29B

Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 11.99$. Total volume : 476.90k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price

Previous Close11.90
Day Range11.82-12.01
Bid11.95 x 2.2k
Ask11.99 x 800
Average Volume955.64k
Market Cap11.29B
52 Week Range10.10-17.89
Trailing P/E85.64
Foward P/E13.94
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03

Financial Details

According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).

Loading ...


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
Total Assets:
Total Cash:

News about "Grifols, S.A."


Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Hold” from Brokerages

Source from : Defense World - 2 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat reports. One ...See details»


Interesting GRFS Put And Call Options For February 2023

Source from : Nasdaq - 4 days ago

I nvestors in Grifols SA, Barcelona (Symbol: GRFS) saw new options become available this week, for the February 2023 expiration. One of the key inputs that goes into the price an ...See details»

Grifols (NASDAQ:GRFS) Sees Large Volume Increase

Source from : Defense World - 4 days ago

Grifols, S.A. (NASDAQ:GRFS – Get Rating) saw unusually-strong trading volume on Tuesday . Approximately 53,256 shares traded hands during mid-day trading, a decline of 92% from the previous session’s ...See details»

Grifols S.A. ADR

Source from : Wall Street Journal - 10 days ago

Grifols SA, Instituto Grifols SA, Grifols USA, Inc., Arrahona Optimus SL Raimon Grifols Roura Joint Chief Executive Officer & Executive Director Grifols Escrow Issuer SA, Grifols SA, Grifols USA ...See details»

Grifols (NASDAQ:GRFS) Shares Gap Down to $11.81

Source from : ETF Daily News - 11 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) gapped down before the market opened on Tuesday . The stock had previously closed at $11.81, but opened at $11.56. Grifols shares last traded ...See details»

Grifols, S.A. (NASDAQ:GRFS) Given Average Recommendation of “Hold” by Analysts

Source from : ETF Daily News - 27 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have been given a consensus rating of “Hold” by the nine research firms that are covering the firm, reports. Two analysts ...See details»

Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond

Source from : Nasdaq - 29 days ago

Shares in Takeda Pharmaceutical (NYSE: TAK), Grifols SA (NASDAQ: GRFS), and Bayer AG (OTC: BAYR.Y) all trade for $20 or less. Of course, being inexpensive doesn't go hand in hand with being a good ...See details»


‘Throw back’ de libro en Grifols

Source from : Capitalbolsa - 5 days ago

La severa corrección de las últimas semanas en Grifols le ha llevado a perder un 14% en menos de un mes. No obstante, por los precios actuales presenta la media de 200 sesiones y el soporte de los 17 ...See details»


Grifols a la espera de sacar partido a sus avances con potencial del 12%

Source from : Estrategias De Inversíon - 5 days ago

La compañía de hemoderivados se concentra en el futuro, porque celebrará antes de que termine el mes su Día del Inversor en el que pondrás sobre la mesa el desempeño de la compañía. De momento el mome ...See details»

Esperando un movimiento brusco en Grifols

Source from : ESPAÑOL - 9 days ago

El precio de las acciones de Grifols lleva varias sesiones que apenas se mueve. Y es que se encuentra atrapado entre las dos medias móviles más importantes que los inversores usan en sus ...See details»


Respondemos a dudas sobre Enagás, Solaria, Grifols, Sabadell o Talgo

Source from : Estrategias De Inversíon - 3 days ago

Damos respuesta a dudas de nuestros lectores sobre valores de bolsa desde el punto del vista técnico con Ángel Cotera, de BBVA Trader.See details»


Grifols. Biotest registra resultados intermedios positivos (valoración)

Source from : Capitalbolsa - 12 days ago

GRIFOLS. Biotest registra resultados intermedios positivos en un ensayo de Fase III con fibrinógeno para el tratamiento en deficiencia adquirida de esta proteína.See details»


Grifols: Potencial recuperación del 17% hacia el objetivo 21,20 euros

Source from : Info Bolsa - 5 days ago

La cotización de Grifols está describiendo un potencial throwback en el área del punto crítico de la figura de HCH invertido, entre 17,30 / 17,64 euros por acción, coincidiendo, además, con la zona de ...See details»

Medical Nutrition Market Size, Growth, Share-Emerging Trends, Market Demand, Industry Analysis, Growth Opportunities and Forecast 2029

Source from : MarketWatch - 4 days ago

The “Medical Nutrition Market” is projected to achieve significant growth by the end of the forecast period as per ...See details»